Author: Steve Kopczak

LitAlert ~~ GeneLit.com

    • Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
    • Satapathy S, Das CK, Aggarwal P, Sood A, Parihar AS, Singh SK, Mittal BR.
    • Prostate. 2022 Oct 19. doi: 10.1002/pros.24450. Epub ahead of print.

    • Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    • Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP.
    • J Clin Oncol. 2022 Oct 18:JCO2102947. doi: 10.1200/JCO.21.02947. Epub ahead of print.

    Related:

    Identifier: NCT02893917: Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 19.)

    • LitAlert ~~ GeneLit.com

    • How should we address the inevitable harms from non-negligent variant reclassification in predictive genetic testing?
    • Rashkin M, Kingham K, Lara-Otero , Mckenna M, Villiers J, Worthington MM, Prince A.
    • J Genet Couns. 2022 Oct 19. doi: 10.1002/jgc4.1638. Epub ahead of print.

    • Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications.
    • Bhardwaj PV, Abdou YG.
    • Curr Oncol Rep. 2022 Oct 18. doi: 10.1007/s11912-022-01340-x. Epub ahead of print.
    • Review

    • LitAlert ~~ GeneLit.com

    • How should we address the inevitable harms from non-negligent variant reclassification in predictive genetic testing?
    • Rashkin M, Kingham K, Lara-Otero , Mckenna M, Villiers J, Worthington MM, Prince A.
    • J Genet Couns. 2022 Oct 19. doi: 10.1002/jgc4.1638. Epub ahead of print.

    • Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications.
    • Bhardwaj PV, Abdou YG.
    • Curr Oncol Rep. 2022 Oct 18. doi: 10.1007/s11912-022-01340-x. Epub ahead of print.
    • Review

    • LitAlert ~~ GeneLit.com

    • How should we address the inevitable harms from non-negligent variant reclassification in predictive genetic testing?
    • Rashkin M, Kingham K, Lara-Otero , Mckenna M, Villiers J, Worthington MM, Prince A.
    • J Genet Couns. 2022 Oct 19. doi: 10.1002/jgc4.1638. Epub ahead of print.

    • IN VIVO ASSIGNMENT OF METHYLMALONIC ACID IN BREAST TISSUE USING 2D MAGNETIC RESONANCE SPECTROSCOPY AND RELATIONSHIP WITH BREAST DENSITY, MENOPAUSAL STATUS AND CANCER RISK.
    • Santamaría G, Naude N, Bennett I, Vosburgh K, Ganau S, Bargalló X, Malycha P, Mountford C.
    • NMR Biomed. 2022 Oct 19:e4851. doi: 10.1002/nbm.4851. Epub ahead of print.

    • Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
    • Satapathy S, Das CK, Aggarwal P, Sood A, Parihar AS, Singh SK, Mittal BR.
    • Prostate. 2022 Oct 19. doi: 10.1002/pros.24450. Epub ahead of print.

    • RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
    • Haynes BM, Cunningham K, Shekhar MPV.
    • BMC Cancer. 2022 Oct 18;22(1):1073. doi: 10.1186/s12885-022-10119-z.

    • Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications.
    • Bhardwaj PV, Abdou YG.
    • Curr Oncol Rep. 2022 Oct 18. doi: 10.1007/s11912-022-01340-x. Epub ahead of print.
    • Review

    • Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    • Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP.
    • J Clin Oncol. 2022 Oct 18:JCO2102947. doi: 10.1200/JCO.21.02947. Epub ahead of print.

    Related:

    Identifier: NCT02893917: Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 19.)

    • Dr. Karlan on Current Research Evaluating PARP Inhibitor Combination Therapy in Ovarian Cancer.
    • Karlan BY.
    • OncLive. OncLive TV. 2022 Oct 18.

    • Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
    • Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP.
    • Breast. 2022 Oct 18:S0960-9776(22)00174-6. doi: 10.1016/j.breast.2022.10.009. Epub ahead of print.

    • Proband-mediated interventions to increase disclosure of genetic risk in families with a BRCA or Lynch syndrome condition: a systematic review.
    • Young AL, Imran A, Spoelma MJ, Williams R, Tucker KM, Halliday J, Forrest LE, Wakefield CE, Butow PN.
    • Eur J Hum Genet. 2022 Oct 17. doi: 10.1038/s41431-022-01200-z. Epub ahead of print.

    • Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study.
    • Shirota H, Komine K, Takahashi M, Takahashi S, Miyauchi E, Niizuma H, Tada H, Shimada M, Niihori T, Aoki Y, Sugiyama I, Kawamura M, Yasuda J, Suzuki S, Iwaya T, Saito M, Saito T, Shibata H, Furukawa T, Ishioka C.
    • Cancer Med. 2022 Oct 17. doi: 10.1002/cam4.5349. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
    • Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP.
    • Breast. 2022 Oct 18:S0960-9776(22)00174-6. doi: 10.1016/j.breast.2022.10.009. Epub ahead of print.

    • Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in the treatment of unresectable pancreatic cancer.
    • Du J, Zhu L, Sha H, Zou Z, Zhao L, Shen J, Kong W, Qiu Y, Liu B.
    • Front Oncol. 2022 Oct 18;12:1015232. doi: 10.3389/fonc.2022.1015232.

    • Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study.
    • Shirota H, Komine K, Takahashi M, Takahashi S, Miyauchi E, Niizuma H, Tada H, Shimada M, Niihori T, Aoki Y, Sugiyama I, Kawamura M, Yasuda J, Suzuki S, Iwaya T, Saito M, Saito T, Shibata H, Furukawa T, Ishioka C.
    • Cancer Med. 2022 Oct 17. doi: 10.1002/cam4.5349. Epub ahead of print.

    • The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
    • Li S, Wang L, Wang Y, Zhang C, Hong Z, Han Z.
    • J Hematol Oncol. 2022 Oct 17;15(1):147. doi: 10.1186/s13045-022-01360-x.

    • A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
    • Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN, Wu HT, Balcioglu M, Sethi H, Scott D, Foran J, McMillan A, Ford JM, Telli ML.
    • Nat Cancer. 2022 Oct 17. doi: 10.1038/s43018-022-00439-1. Epub ahead of print.

    Related:

    Identifier: NCT02401347: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Oct 18.)

    Identifier: NCT04756765: Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 18.)

    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 3: PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 17.

    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 4: Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 17.